Longitudinal Analysis of MART-1/HLA-A2-Reactive T Cells over the Course of Melanoma Progression

Scandinavian Journal of Immunology

Volumn 58, Issue 5, 2003, Pages 566-571

  Terheyden, P ^a   Schrama, D ^a   Pedersen, L O ^b   Andersen, M H ^b   Kampgen E ^a   Thor Straten, P ^b   Becker, J C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; EPITOPE; GAMMA INTERFERON; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; HLA A2 ANTIGEN; INTERLEUKIN 2; IONOMYCIN; ISOLEUCYLMETHIONYLASPARTYLGLUTAMINYLVALYLPROLYLPHENYLALANYLSERYLVALINE; MELAN A; MELANOMA ANTIGEN; PEPTIDE; PHENYLALANYLLEUCYLTRYPTOPHYLGLYCYLPROLYLARGINYLALANYLLEUCYLVALINE; PHORBOL 13 ACETATE 12 MYRISTATE; TEMOZOLOMIDE; TETRAMER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIOLOGICAL MONITORING; BLOOD CELL; BRAIN METASTASIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CASE REPORT; CELL COUNT; CELL ISOLATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; LONGITUDINAL STUDY; LUNG METASTASIS; LYMPH NODE METASTASIS; LYMPHOCYTE CLONE; MALE; MELANOMA; PRIORITY JOURNAL; STAINING; T LYMPHOCYTE; VACCINATION;

ANTIGENS, NEOPLASM; DISEASE PROGRESSION; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; INTERLEUKIN-2; LONGITUDINAL STUDIES; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES;

EID: 0242574495     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01324.x     Document Type: Article

References (19)

1. Rivoltini L, Carraba M, Huber V et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol Rev 2002;188:97-113.
2. + T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002;32:731-41.
3. Pittet MJ, Valmori D, Dunbar PR et al. High frequencies of naive melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-15.
4. Becker JC, Terheyden P, Bröcker EB. Molecular basis of T-cell dys-function in melanoma. Melanoma Res 1997;7 (Suppl. 2):S51-S57.
5. Zea AH, Curti BD, Longo DL et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-35.
6. Dunbar PR, Smith CL, Chao D et al. A shift in the phenotype of melan-A-specific CTL identifies melanoma patients with an active tumor-specific immune tesponse. J Immunol 2000;165:6644-52.
7. + T cells. J Immunol 2000;165:2287-96.
8. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002;29:5-11.
9. Andersen MH, Keikavoussi P, Bröcker EB et al. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: cessation of CTL responses is associated with disease progression. Int J Cancet 2001;94:820-4.
10. Schrama D, Andersen MH, Terheyden P et al. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res 2001;61:493-6.
11. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am 1998;4:316-23.
12. Valmori D, Fonteneau JF, Lizana CM et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998;160: 1750-8.
13. Grabbe S, Bruvers S, Gallo RL et al. Tumor antigen presentation by murine epidermal cells. J Immunol 1991;146:3656-61.
14. Thurner B, Roder C, Dieckmann D et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 1999;223:1-15.
15. Altman JD, Moss PA, Goulder PJ et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-6.
16. + T cells usable in immunotherapy. Nat Biotechnol 1998;16:281-5.
17. thor Straten P, Barfoed A, Seremet T et al. Detection and characterization of alpha-beta-T-cell clonality by denaturing gradient gel electrophoresis (DGGE). Biotechniques 1998;25:244-50.
18. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
19. Kaech SM, Wherry J, Ahmed R. Effector and memory T cell differentiation: implications fot vaccine development. Nat Rev Immunol 2002;2:251-62.